Cardiovascular disease (CVD) is a leading cause of morbidity and mortality among patients with diabetes. As such, healthcare professionals must be equipped with strategies to assess and mitigate cardiovascular risk in this population.
Cardiovascular risk assessment should be a routine part of diabetes management. The American Diabetes Association recommends using a validated tool, such as the UKPDS risk engine, which considers factors like age, sex, ethnicity, smoking status, and HbA1c levels. It is also essential to monitor for symptoms of CVD and carry out regular blood pressure, lipid profile, and renal function tests.
Hyperglycemia is a significant risk factor for CVD. Therefore, achieving and maintaining glycemic control is crucial. Individualized HbA1c targets should be set, and a combination of lifestyle modification and pharmacotherapy should be used to achieve these targets. Drugs like metformin, GLP-1 receptor agonists, and SGLT2 inhibitors have shown cardiovascular benefits in addition to their glucose-lowering effects.
Besides hyperglycemia, other risk factors like hypertension, dyslipidemia, and obesity should also be addressed. Hypertension should be managed with lifestyle changes and antihypertensive medications, aiming for a target blood pressure of <130/80 mmHg. Dyslipidemia should be treated with statins, and in some cases, ezetimibe or PCSK9 inhibitors. Weight management strategies, including dietary changes, physical activity, and sometimes bariatric surgery, should be implemented for overweight or obese patients.
Managing cardiovascular risk in diabetic patients requires a comprehensive, multifaceted approach that involves regular risk assessment, glycemic control, and management of other cardiovascular risk factors. By adopting these strategies, healthcare professionals can significantly improve the cardiovascular health and overall prognosis of their diabetic patients.
1.
Talquetamab Combos Show Survival Benefit in r/r Myeloma
2.
From sweetener to cancer fighter? Fermented stevia shows promise in pancreatic cancer study
3.
Year in Review: Non-Small Cell Lung Cancer
4.
FINAL USPSTF RECOMMENDATIONS ON ANXIETY, DEPRESSION, AND SUIICIDAL RISK.
5.
Liposomal Chemo Combination No Better Than Standard Induction in Pediatric AML
1.
Targeted Therapies for Breast Cancer: What’s New?
2.
Ultrasound: A Promising Tool in the Fight Against Malignant Breast Cancer
3.
Adjuvant Atezolizumab in TNBC: What Recent Trials Reveal About Its Role
4.
Revolutionizing Cancer Care: The Transformative Role of AI and Data Science in Oncology
5.
Sorafenib: Understanding the science behind a powerful cancer drug
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion
2.
ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
4.
Common Cancer Myths Debunked
5.
Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation